COVID-19 killed the bull market in stocks this year, but at least one stock hasn’t been fazed by the virus. To the contrary, Gilead Sciences (GILD), maker of the Ebola drug-turned-coronavirus drug remdesivir, is enjoying its own private bull market, with its shares up 27% since the year began.On Wednesday, Gilead shared some of its good fortune with the rest of the stock market, too, as a pair of new remdesivir data releases helped spark a rally that sent the S&P 500 up 2.7%.So what did Gilead have to say today?Firstly, according to the company, a National Institute of Allergy …read more
Source:: Yahoo Finance
